86-5925-19　anti- SIRT4 antibody 100ug　FNab07882

特徴

• Background：Acts as NAD-dependent protein lipoamidase, ADP-ribosyl transferase and deacetylase(PubMed:19220062). Catalyzes more efficiently removal of lipoyl-and biotinyl-than acetyl-lysine modifications. Inhibits the pyruvate dehydrogenase complex(PDH) activity via the enzymatic hydrolysis of the lipoamide cofactor from the E2 component, DLAT, in a phosphorylation-independent manner(PubMed:25525879). Catalyzes the transfer of ADP-ribosyl groups onto target proteins, including mitochondrial GLUD1, inhibiting GLUD1 enzyme activity. Acts as a negative regulator of mitochondrial glutamine metabolism by mediating mono ADP-ribosylation of GLUD1: expressed in response to DNA damage and negatively regulates anaplerosis by inhibiting GLUD1, leading to block metabolism of glutamine into tricarboxylic acid cycle and promoting cell cycle arrest(PubMed:16959573). In response to mTORC1 signal, SIRT4 expression is repressed, promoting anaplerosis and cell proliferation(PubMed:23663782). Acts as a tumor suppressor(PubMed:23562301, PubMed:23663782). Also acts as a NAD-dependent protein deacetylase: mediates deacetylation of 'Lys-471' of MLYCD, inhibiting its activity, thereby acting as a regulator of lipid homeostasis(PubMed:23746352). Controls fatty acid oxidation by inhibiting PPARA transcriptional activation. Impairs SIRT1:PPARA interaction probably through the regulation of NAD(+) levels(PubMed:24043310, PubMed:20685656). Down-regulates insulin secretion(By similarity).